{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:39:43Z","timestamp":1791394783631,"version":"4.3.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Major Project for Significant New Drugs Development, Platform for Postmarketing Evaluation of New Drugs for Rare Diseases","award":["2017ZX09304029-006-001"],"award-info":[{"award-number":["2017ZX09304029-006-001"]}]},{"name":"National Science and Technology Major Project for Significant New Drugs Development, Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Pediatric Rare Diseases","award":["2017ZX09304029-006"],"award-info":[{"award-number":["2017ZX09304029-006"]}]},{"name":"National Science and Technology Major Project for Significant New Drugs Development, Platform for Research and Development and Industrialization of Pediatric Urgent Drugs in Short Supply","award":["2017ZX09721003-008"],"award-info":[{"award-number":["2017ZX09721003-008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple sclerosis (MS) is a chronic illness involving the central nervous system (CNS) that is characterised by inflammation, demyelination, and degenerative changes. Dalfampridine is one of the available treatments for MS symptoms and comorbidities. This meta-analysis aimed to assess the safety and benefits of dalfampridine versus placebo in MS by summarising data deriving from previously published clinical randomised controlled studies (RCTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 9 RCTs were included in this meta-analysis, involving 1691 participants. There were significant differences between dalfampridine and placebo in terms of decreased 12-item Multiple Sclerosis Walking Scale score (weighted mean difference [WMD]\u2009=\u2009\u2009\u2212\u20093.68, 95% confidence interval [CI] [\u2212\u20095.55,\u2009\u2212\u20091.80], <jats:italic>p<\/jats:italic>\u2009=\u20090.0001), improved response to the timed 25-foot walk test (relative risk [RR]\u2009=\u20092.57, 95% CI [1.04, 6.33], <jats:italic>p<\/jats:italic>\u2009=\u20090.04), increased 6-min walk test (WMD\u2009=\u200918.40, 95% CI [1.30, 35.51], <jats:italic>p<\/jats:italic>\u2009=\u20090.03), increased 9-Hole Peg Test score (WMD\u2009=\u20091.33, 95% CI [0.60, 2.05], <jats:italic>p<\/jats:italic>\u2009=\u20090.0004), and increased Symbol Digit Modalities Test score (WMD\u2009=\u20094.47, 95% CI [3.91, 5.02], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001). Significant differences in the incidence of side effects were also observed (RR\u2009=\u20091.12, 95% CI [1.04, 1.21], <jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Dalfampridine exerts positive effects on walking ability, finger dexterity, and cognitive function. Treatment should be administered under the guidance of a physician or pharmacist given the higher incidence of adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01694-8","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:23:12Z","timestamp":1613571792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials"],"prefix":"10.1186","volume":"16","author":[{"given":"Enyao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1005","authenticated-orcid":false,"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"2","key":"1694_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol. 2018;25(2):605. https:\/\/doi.org\/10.1111\/ene.13536.","journal-title":"Eur J Neurol"},{"issue":"10130","key":"1694_CR2","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1.","journal-title":"Lancet"},{"issue":"8","key":"1694_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123\u201336. https:\/\/doi.org\/10.1177\/1352458517694432.","journal-title":"Mult Scler"},{"issue":"12","key":"1694_CR4","first-page":"665","volume":"35","author":"R Lamore III","year":"2010","unstructured":"Lamore R III, Jacob E, Jacob SC, Hilas O. Dalfampridine (Ampyra): an aid to walking in patients with multiple sclerosis. P T Peer Rev J Formul Manag. 2010;35(12):665\u20139.","journal-title":"P T Peer Rev J Formul Manag"},{"issue":"1","key":"1694_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis\u2014a review. Eur J Neurol. 2019;26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819.","journal-title":"Eur J Neurol"},{"issue":"3","key":"1694_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18553\/jmcp.2007.13.3.287","volume":"13","author":"FR Curtiss","year":"2007","unstructured":"Curtiss FR. Pharmacoeconomic modeling of drug therapies for multiple sclerosis\u2014are we building houses on sand? J Manag Care Pharm. 2007;13(3):287\u20139. https:\/\/doi.org\/10.18553\/jmcp.2007.13.3.287.","journal-title":"J Manag Care Pharm"},{"issue":"2","key":"1694_CR7","first-page":"139","volume":"16","author":"KM Stockl","year":"2010","unstructured":"Stockl KM, Shin JS, Gong S, Harada AS, Solow BK, Lew HC. Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care. 2010;16(2):139\u201344.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1694_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1527-3458.2004.tb00029.x","volume":"10","author":"KC Hayes","year":"2004","unstructured":"Hayes KC. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004;10(4):295\u2013316. https:\/\/doi.org\/10.1111\/j.1527-3458.2004.tb00029.x.","journal-title":"CNS Drug Rev"},{"key":"1694_CR9","unstructured":"Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2018. https:\/\/www.accessdata.fda\/gov. Cited 26 Sept 2018. Retrieved from: http:\/\/fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&applno=022250."},{"issue":"9","key":"1694_CR10","doi-asserted-by":"publisher","first-page":"e0222288","DOI":"10.1371\/journal.pone.0222288","volume":"14","author":"J Shi","year":"2019","unstructured":"Shi J, Wu X, Chen Y. Study on dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: a meta-analysis. PLoS ONE. 2019;14(9):e0222288. https:\/\/doi.org\/10.1371\/journal.pone.0222288.","journal-title":"PLoS ONE"},{"issue":"11","key":"1694_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40263-019-00671-x","volume":"33","author":"M Valet","year":"2019","unstructured":"Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S, et al. Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2019;33(11):1087\u201399. https:\/\/doi.org\/10.1007\/s40263-019-00671-x.","journal-title":"CNS Drugs"},{"issue":"6","key":"1694_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Ann Neurol. 2005;58(6):840\u20136. https:\/\/doi.org\/10.1002\/ana.20703.","journal-title":"Ann Neurol"},{"issue":"2","key":"1694_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366.","journal-title":"Ann Neurol"},{"issue":"11","key":"1694_CR14","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"issue":"1","key":"1694_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","volume":"33","author":"J Hobart","year":"2019","unstructured":"Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, et al. Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE trial of prolonged-release fampridine. CNS Drugs. 2019;33(1):61\u201379. https:\/\/doi.org\/10.1007\/s40263-018-0586-5.","journal-title":"CNS Drugs"},{"issue":"2","key":"1694_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1352458515581436","volume":"22","author":"R Hupperts","year":"2016","unstructured":"Hupperts R, Lycke J, Short C, Gasperini C, McNeill M, Medori R, et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult Scler. 2016;22(2):212\u201321. https:\/\/doi.org\/10.1177\/1352458515581436.","journal-title":"Mult Scler"},{"issue":"3","key":"1694_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7224\/1537-2073.2014-040","volume":"17","author":"R Yapundich","year":"2015","unstructured":"Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, et al. Evaluation of dalfampridine extended release 5 and 10 mg in Multiple Sclerosis: a randomized controlled trial. Int J MS Care. 2015;17(3):138\u201345. https:\/\/doi.org\/10.7224\/1537-2073.2014-040.","journal-title":"Int J MS Care"},{"issue":"4","key":"1694_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494\u2013502. https:\/\/doi.org\/10.1002\/ana.22240.","journal-title":"Ann Neurol"},{"key":"1694_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","volume":"10","author":"HB Jensen","year":"2016","unstructured":"Jensen HB, Nielsen JL, Ravnborg M, Dalgas U, Aagaard P, Stenager E. Effect of slow release-fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study. Mult Scler Relat Disord. 2016;10:137\u201344. https:\/\/doi.org\/10.1016\/j.msard.2016.07.019.","journal-title":"Mult Scler Relat Disord"},{"key":"1694_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318761168","author":"F Jacques","year":"2018","unstructured":"Jacques F, Schembri A, Nativ A, Paquette C, Kalinowski P. Prolonged-release fampridine as adjunct therapy to active motor training in MS Patients: a pilot, double-blind, randomized, placebo-controlled study. Mult Scler J Exp Transl Clin. 2018. https:\/\/doi.org\/10.1177\/2055217318761168.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"1694_CR21","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1212\/WNL.0000000000007970","volume":"93","author":"L De Giglio","year":"2019","unstructured":"De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, et al. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019;93(8):e733\u201346. https:\/\/doi.org\/10.1212\/WNL.0000000000007970.","journal-title":"Neurology"},{"key":"1694_CR22","doi-asserted-by":"publisher","first-page":"101971","DOI":"10.1016\/j.msard.2020.101971","volume":"40","author":"S Marion","year":"2020","unstructured":"Marion S, Leonid C, Belinda B, Joanne D, Elise H, Leeanne C, et al. Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2020;40:101971. https:\/\/doi.org\/10.1016\/j.msard.2020.101971.","journal-title":"Mult Scler Relat Disord"},{"key":"1694_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.12.026","volume":"28","author":"C Arreola-Mora","year":"2019","unstructured":"Arreola-Mora C, Silva-Pereyra J, Fern\u00e1ndez T, Paredes-Cruz M, Bertado-Cort\u00e9s B, Grijalva I. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: randomized, double-blind, placebo-controlled clinical trial. Preliminary report [preliminary report]. Mult Scler Relat Disord. 2019;28:117\u201324. https:\/\/doi.org\/10.1016\/j.msard.2018.12.026.","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"1694_CR24","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1212\/WNL.0b013e31828cf7f3","volume":"80","author":"J Hobart","year":"2013","unstructured":"Hobart J, Blight AR, Goodman A, Lynn F, Putzki N. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Neurology. 2013;80(16):1509\u201317. https:\/\/doi.org\/10.1212\/WNL.0b013e31828cf7f3.","journal-title":"Neurology"},{"key":"1694_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/PROM.S96956","volume":"7","author":"MF Sidovar","year":"2016","unstructured":"Sidovar MF, Limone BL, Coleman CI. Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort. Patient Relat Outcome Meas. 2016;7:13\u20138. https:\/\/doi.org\/10.2147\/PROM.S96956.","journal-title":"Patient Relat Outcome Meas"},{"issue":"7","key":"1694_CR26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1177\/1352458512444498","volume":"18","author":"BC Kieseier","year":"2012","unstructured":"Kieseier BC, Pozzilli C. Assessing walking disability in multiple sclerosis. Mult Scler. 2012;18(7):914\u201324. https:\/\/doi.org\/10.1177\/1352458512444498.","journal-title":"Mult Scler"},{"issue":"1","key":"1694_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/135245850100700110","volume":"7","author":"KM Myhr","year":"2001","unstructured":"Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gr\u00f8nning R, Midgard R, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler. 2001;7(1):59\u201365. https:\/\/doi.org\/10.1177\/135245850100700110.","journal-title":"Mult Scler"},{"issue":"10","key":"1694_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/qjmed\/hch105","volume":"97","author":"L Hemmett","year":"2004","unstructured":"Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? Q J Med. 2004;97(10):671\u20136. https:\/\/doi.org\/10.1093\/qjmed\/hch105.","journal-title":"Q J Med"},{"issue":"3","key":"1694_CR29","first-page":"127","volume":"4","author":"K Edgley","year":"1991","unstructured":"Edgley K, Sullivan MJ, Dehoux E. A survey of multiple sclerosis: II. Determinants of employment status. Can J Rehabil. 1991;4(3):127\u201332.","journal-title":"Can J Rehabil"},{"issue":"6","key":"1694_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7326\/0003-4819-114-6-451","volume":"114","author":"DR Calkins","year":"1991","unstructured":"Calkins DR, Rubenstein LV, Cleary PD, Davies AR, Jette AM, Fink A, et al. Failure of physicians to recognize functional disability in ambulatory patients. Ann Intern Med. 1991;114(6):451\u20134. https:\/\/doi.org\/10.7326\/0003-4819-114-6-451.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1694_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s004150170198","volume":"248","author":"JA Freeman","year":"2001","unstructured":"Freeman JA. Improving mobility and functional independence in persons with multiple sclerosis. J Neurol. 2001;248(4):255\u20139. https:\/\/doi.org\/10.1007\/s004150170198.","journal-title":"J Neurol"},{"key":"1694_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-07271-0.50008-2","volume-title":"The symptoms and signs of multiple sclerosis","author":"I McDonald","year":"2006","unstructured":"McDonald I, Compston A. The symptoms and signs of multiple sclerosis. London: Churchill Livingstone; 2006."},{"issue":"6","key":"1694_CR33","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.apmr.2012.01.008","volume":"93","author":"CP Kamm","year":"2012","unstructured":"Kamm CP, Heldner MR, Vanbellingen T, Mattle HP, M\u00fcri R, Bohlhalter S. Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living. Arch Phys Med Rehabil. 2012;93(6):1081\u20135. https:\/\/doi.org\/10.1016\/j.apmr.2012.01.008.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1\u20132","key":"1694_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jns.2014.03.047","volume":"341","author":"MW Koch","year":"2014","unstructured":"Koch MW, Murray TJ, Fisk J, Greenfield J, Bhan V, Jacobs P, et al. Hand dexterity and direct disease related cost in multiple sclerosis. J Neurol Sci. 2014;341(1\u20132):51\u20134. https:\/\/doi.org\/10.1016\/j.jns.2014.03.047.","journal-title":"J Neurol Sci"},{"issue":"4","key":"1694_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3233\/NRE-130917","volume":"32","author":"A Kalron","year":"2013","unstructured":"Kalron A, Greenberg-Abrahami M, Gelav S, Achiron A. Effects of a new sensory re-education training tool on hand sensibility and manual dexterity in people with multiple sclerosis. NeuroRehabilitation. 2013;32(4):943\u20138. https:\/\/doi.org\/10.3233\/NRE-130917.","journal-title":"NeuroRehabilitation"},{"issue":"12","key":"1694_CR36","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1177\/1352458514565959","volume":"21","author":"CP Kamm","year":"2015","unstructured":"Kamm CP, Mattle HP, M\u00fcri RM, Heldner MR, Blatter V, Bartlome S, et al. Home-based training to improve manual dexterity in patients with multiple sclerosis: a randomized controlled trial. Mult Scler. 2015;21(12):1546\u201356. https:\/\/doi.org\/10.1177\/1352458514565959.","journal-title":"Mult Scler"},{"issue":"1","key":"1694_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MRR.0000000000000209","volume":"40","author":"M Hervault","year":"2017","unstructured":"Hervault M, Balto JM, Hubbard EA, Motl RW. Reliability, precision, and clinically important change of the Nine-Hole Peg Test in individuals with multiple sclerosis. Int J Rehabil Res. 2017;40(1):91\u20133. https:\/\/doi.org\/10.1097\/MRR.0000000000000209.","journal-title":"Int J Rehabil Res"},{"issue":"8","key":"1694_CR38","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00415-015-7797-1","volume":"262","author":"E Allart","year":"2015","unstructured":"Allart E, Benoit A, Blanchard-Dauphin A, Tiffreau V, Thevenon A, Zephir H, et al. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. J Neurol. 2015;262(8):1936\u201345. https:\/\/doi.org\/10.1007\/s00415-015-7797-1.","journal-title":"J Neurol"},{"issue":"2","key":"1694_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1756285613512712","volume":"7","author":"HB Jensen","year":"2014","unstructured":"Jensen HB, Ravnborg M, Dalgas U, Stenager E. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7(2):97\u2013113. https:\/\/doi.org\/10.1177\/1756285613512712.","journal-title":"Ther Adv Neurol Disord"},{"key":"1694_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","volume":"139","author":"K Pavsic","year":"2015","unstructured":"Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35\u201340. https:\/\/doi.org\/10.1016\/j.clineuro.2015.08.023.","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"1694_CR41","doi-asserted-by":"publisher","first-page":"e71058","DOI":"10.1371\/journal.pone.0071058","volume":"8","author":"A Achiron","year":"2013","unstructured":"Achiron A, Chapman J, Magalashvili D, et al. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE. 2013;8(8):e71058. https:\/\/doi.org\/10.1371\/journal.pone.0071058.","journal-title":"PLoS ONE"},{"issue":"2","key":"1694_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000177940","volume":"61","author":"J Olazar\u00e1n","year":"2009","unstructured":"Olazar\u00e1n J, Cruz I, Benito-Le\u00f3n J, Morales JM, Duque P, Rivera-Navarro J. Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study. Eur Neurol. 2009;61(2):87\u201393. https:\/\/doi.org\/10.1159\/000177940.","journal-title":"Eur Neurol"},{"issue":"5","key":"1694_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1212\/wnl.41.5.685","volume":"41","author":"SM Rao","year":"1991","unstructured":"Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685\u201391. https:\/\/doi.org\/10.1212\/wnl.41.5.685.","journal-title":"Neurology"},{"issue":"9 Suppl 2","key":"1694_CR44","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1212\/WNL.0000000000002883","volume":"87","author":"MP Amato","year":"2016","unstructured":"Amato MP, Krupp LB, Charvet LE, Penner I, Till C. Pediatric multiple sclerosis: cognition and mood. Neurology. 2016;87(9 Suppl 2):S82\u20137. https:\/\/doi.org\/10.1212\/WNL.0000000000002883.","journal-title":"Neurology"},{"issue":"1","key":"1694_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/0883073812464816","volume":"28","author":"L Julian","year":"2013","unstructured":"Julian L, Serafin D, Charvet L, Ackerson J, Benedict R, Braaten E, et al. Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol. 2013;28(1):102\u20137. https:\/\/doi.org\/10.1177\/0883073812464816.","journal-title":"J Child Neurol"},{"issue":"3","key":"1694_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10865-010-9247-y","volume":"33","author":"JM Bruce","year":"2010","unstructured":"Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33(3):219\u201327. https:\/\/doi.org\/10.1007\/s10865-010-9247-y.","journal-title":"J Behav Med"},{"issue":"2","key":"1694_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","volume":"53","author":"MW Geisler","year":"1996","unstructured":"Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol. 1996;53(2):185\u20138. https:\/\/doi.org\/10.1001\/archneur.1996.00550020101021.","journal-title":"Arch Neurol"},{"key":"1694_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.msard.2016.10.011","volume":"11","author":"SA Morrow","year":"2017","unstructured":"Morrow SA, Rosehart H, Johnson AM. The effect of fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. Mult Scler Relat Disord. 2017;11:4\u20139. https:\/\/doi.org\/10.1016\/j.msard.2016.10.011.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"1694_CR49","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/1352458511404585","volume":"17","author":"JF Sumowski","year":"2011","unstructured":"Sumowski JF, Chiaravalloti N, Erlanger D, Kaushik T, Benedict RH, DeLuca J. L-amphetamine improves memory in MS patients with objective memory impairment. Mult Scler. 2011;17(9):1141\u20135. https:\/\/doi.org\/10.1177\/1352458511404585.","journal-title":"Mult Scler"},{"issue":"7","key":"1694_CR50","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00415-009-5074-x","volume":"256","author":"SA Morrow","year":"2009","unstructured":"Morrow SA, Kaushik T, Zarevics P, Erlanger D, Bear MF, Munschauer FE, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095\u2013102. https:\/\/doi.org\/10.1007\/s00415-009-5074-x.","journal-title":"J Neurol"},{"issue":"2","key":"1694_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00415-012-6663-7","volume":"260","author":"SA Morrow","year":"2013","unstructured":"Morrow SA, Smerbeck A, Patrick K, Cookfair D, Weinstock-Guttman B, Benedict RH. Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. J Neurol. 2013;260(2):489\u201397. https:\/\/doi.org\/10.1007\/s00415-012-6663-7.","journal-title":"J Neurol"},{"key":"1694_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jns.2016.02.012","volume":"363","author":"L Peyro Saint Paul","year":"2016","unstructured":"Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, et al. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study. J Neurol Sci. 2016;363:69\u201376. https:\/\/doi.org\/10.1016\/j.jns.2016.02.012.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1694_CR53","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/1352458511412061","volume":"17","author":"S Huolman","year":"2011","unstructured":"Huolman S, H\u00e4m\u00e4l\u00e4inen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, et al. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Mult Scler. 2011;17(11):1351\u201361. https:\/\/doi.org\/10.1177\/1352458511412061.","journal-title":"Mult Scler"},{"issue":"9","key":"1694_CR54","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1212\/01.wnl.0000142989.09633.5a","volume":"63","author":"LB Krupp","year":"2004","unstructured":"Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63(9):1579\u201385. https:\/\/doi.org\/10.1212\/01.wnl.0000142989.09633.5a.","journal-title":"Neurology"},{"key":"1694_CR55","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/DHPS.S97113","volume":"7","author":"M Jara","year":"2015","unstructured":"Jara M, Aquilina T, Aupperle P, Rabinowicz AL. Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug Healthc Patient Saf. 2015;7:169\u201374. https:\/\/doi.org\/10.2147\/DHPS.S97113.","journal-title":"Drug Healthc Patient Saf"},{"key":"1694_CR56","unstructured":"Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2019. Cited 19 Dec 2019. Retrieved from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/22250s017lbl.pdf."},{"issue":"7\u20138","key":"1694_CR57","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1345\/aph.1Q714","volume":"46","author":"TE Pikoulas","year":"2012","unstructured":"Pikoulas TE, Fuller MA. Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012;46(7\u20138):1010\u20135. https:\/\/doi.org\/10.1345\/aph.1Q714.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"1694_CR58","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","volume":"90","author":"JF Sumowski","year":"2018","unstructured":"Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000004977.","journal-title":"Neurology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01694-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:41:16Z","timestamp":1613572876000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01694-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1694"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01694-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}